Literature DB >> 16103495

Effect of thiazolidinediones on lipid profile.

Pankaj Madan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103495      PMCID: PMC1188204          DOI: 10.1503/cmaj.1050034

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  7 in total

1.  Rosiglitazone monotherapy is effective in patients with type 2 diabetes.

Authors:  H E Lebovitz; J F Dole; R Patwardhan; E B Rappaport; M I Freed
Journal:  J Clin Endocrinol Metab       Date:  2001-01       Impact factor: 5.958

Review 2.  Oral antihyperglycemic therapy for type 2 diabetes mellitus.

Authors:  Alice Y Y Cheng; I George Fantus
Journal:  CMAJ       Date:  2005-01-18       Impact factor: 8.262

3.  The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.

Authors:  S Rosenblatt; B Miskin; N B Glazer; M J Prince; K E Robertson
Journal:  Coron Artery Dis       Date:  2001-08       Impact factor: 1.439

4.  A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.

Authors:  P Raskin; M Rendell; M C Riddle; J F Dole; M I Freed; J Rosenstock
Journal:  Diabetes Care       Date:  2001-07       Impact factor: 19.112

5.  Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

Authors:  V Fonseca; J Rosenstock; R Patwardhan; A Salzman
Journal:  JAMA       Date:  2000-04-05       Impact factor: 56.272

6.  Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.

Authors:  M S Kipnes; A Krosnick; M S Rendell; J W Egan; A L Mathisen; R L Schneider
Journal:  Am J Med       Date:  2001-07       Impact factor: 4.965

7.  Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.

Authors:  J Rosenstock; D Einhorn; K Hershon; N B Glazer; S Yu
Journal:  Int J Clin Pract       Date:  2002-05       Impact factor: 2.503

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.